RJA
ALNY icon

Ross\Johnson & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ross\Johnson & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301 Hold
1
– – ﹤0.01% 189
2026
Q1 		$331 Hold
1
– – 0.01% 131
2025
Q4 		$398 Hold
1
– – 0.01% 174
2025
Q3 		$456 Hold
1
– – 0.01% 111
2025
Q2 		$326 Hold
1
– – 0.01% 134
2025
Q1 		$270 Buy
+1
New +$257 ﹤0.01% 298

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ross\Johnson & Associates's ALNY Position: Q2 2026 in Review

Ross\Johnson & Associates held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1 share worth $301. The position accounts for ﹤0.01% of the portfolio, ranked #189.

Ross\Johnson & Associates first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $456 in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ross\Johnson & Associates held 1 share of Alnylam Pharmaceuticals worth $301 as of Q2 2026.
  • Ross\Johnson & Associates left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #189 holding.
  • Ross\Johnson & Associates first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Ross\Johnson & Associates's Alnylam Pharmaceuticals position peaked at $456 in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.